Treatment for Acne Vulgaris

Acne is the most common skin disease in the US and affects 80% of the population at some point in life.

» Study Details | Apply for the Study

Upcoming Studies for Men & Women

» Study Details | Apply for the Study

Irritable Bowel Syndrome Experiencing Abdominal Pain

The CAPTIVATE Study is a clinical study to evaluate how an investigational study medication called olorinab may reduce abdominal pain in people with IBS. You are being asked to see if you qualify in this study. The investigational study medication has been previously tested in healthy volunteers and in a small group of people with Crohn’s disease experiencing abdominal pain. The investigational study treatment in the CAPTIVATE Study is taken orally 3 times a day. This study is designed to evaluate whether olorinab can reduce abdominal pain associated with IBS.

You may be eligible to participate in this study if you: are

18-70 years of age have been diagnosed with IBS with constipation or diarrhea (IBS-C or IBS-D) experience abdominal pain due to IBS  

Other eligibility criteria apply.

Eligible participants will receive study-related health assessments and study-related treatment (olorinab or placebo) at no cost. You'll be paid for each completed visit. Enrollment is currently open for this study.

» Study Details | Apply for the Study

Celiac Disease on a Gluten Free Diet

If you are experiencing celiac disease symptoms despite following a gluten-free diet, you may want to talk to your doctor about our clinical study.

» Study Details | Apply for the Study

Ulcerative Colitis Study

A 54-Week Treatment, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo and Active-Controlled, Parallel-Group Phase 2 Study to Assess the Efficacy and Safety of Brazikumab in Participants with Moderately to Severely Active Ulcerative Colitis

» Study Details | Apply for the Study

Moderately to Severely Active Crohn’s Disease

A 52-Week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo and Active-Controlled, Operationally Seamless Phase 2b/3, Parallel-group Study to Assess the Efficacy and Safety of Brazikumab in Participants with Moderately to Severely Active Crohn’s Disease

» Study Details | Apply for the Study

Non-Alcoholic Steatohepatitis (NASH)

A Phase 2b Randomized, Double Blind, Placebo-Controlled, Multicenter Study Evaluating Safety and Efficacy of EDP-305 in Subjects with Liver-Biopsy Proven Non-Alcoholic Steatohepatitis (NASH)

» Study Details | Apply for the Study

Moderate to Severe Endometriosis-Associated Pain

Endometriosis is a chronic oestrogen-dependent condition characterised by the growth of endometrial tissue in sites other than the uterine cavity, most commonly the pelvic cavity (including the ovaries), the uterosacral ligaments, the pouch of Douglas, the rectosigmoid colon, and the bladder and distal ureter

» Study Details | Apply for the Study

heavy menstrual bleeding associated with uterine fibroids in premenopausal

Heavy Menstrual Bleeding Associated with Uterine Fibroids

» Study Details | Apply for the Study

Hot Flashes Associated with Menopause

Moderate to Severe Vasomotor Symptoms (Hot Flashes) Associated with Menopause

» Study Details | Apply for the Study

Adaptive Platform Treatment Trial for Outpatients with COVID-19

Adapt Out COVID is a master protocol to evaluate the safety and efficacy of investigational agents for the treatment of symptomatic non-hospitalized adults with COVID-19.

» Study Details | Apply for the Study

COVID-19 Treatment Clinical Trial

A Phase 3 Randomized, Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of COVID-19 in an Outpatient Setting

» Study Details | Apply for the Study

Moderate to Severe Atopic Dermatitis in Adolescent

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent Subjects with Moderate to Severe Atopic Dermatitis

» Study Details | Apply for the Study